US biotech Abcuro has reeled in $200 million in third-round financing that should allow it to complete its pivotal trial of ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

The Janus Henderson Global Life Sciences Fund returned -11.16% and the MSCI World Health Care IndexSM returned -11.40%. Click ...

It is not known whether Octagam 10% can cause fetal harm when administered ... where she serves as Co-Director of the Myositis Center and Director of Clinical Trials. She earned her undergraduate ...

The following is a summary of “Validity of diagnosis codes to identify a dermatomyositis cohort from electronic health records,” published in the January 2025 issue of Dermatology by Silberzweig et al ...

Ongoing launch of CASGEVY ® continues to gain momentum; new cell patient collection initiations expected to significantly grow in 2025- -More than 50 authorized treatment centers (ATCs) activated ...

There is an underdiagnosed condition called statin-induced autoimmune myopathy. It can take years to show up and can be hard to treat.

Cyngn Inc. announced that all outstanding Series B cashless warrants have been fully exercised. These warrants were originally issued in connection with a public offering that closed on December 23, ...

Ongoing launch of CASGEVY® continues to gain momentum; new cell patient collection initiations expected to significantly ...

On the third trip to the hospital, one doctor asked how long I had been on statins and remarked that they sometimes cause side effects ... To learn more about the side effects of statins and myositis, ...

Myopathic (myo = muscle, pathy = disease) conditions can include polymyositis, dermatomyositis, inclusion body myositis, and various myopathies due to metabolic, congenital, and endocrine causes.

Although generally well-tolerated, several reports suggest that it can rarely cause myositis. We present a case of gemcitabine-induced myositis in a patient with pancreatic adenocarcinoma and review ...